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Resumo 
 
Introdução: O linfoma folicular é o segundo linfoma Não-Hodgkin mais comum, constituindo 
cerca de 20% dos casos diagnosticados de novo em adultos e o mais comum dentro dos linfomas 
indolentes. É reconhecido como um grupo heterogéneo de distúrbios. O follicular lymphoma 
international prognostic index permite a estratificação dos doentes, mas fornece apenas uma 
estimativa aproximada da evolução da doença. No entanto, têm surgido novos marcadores de 
prognóstico. Alterações epigenéticas têm vindo a ser demonstradas como sendo uma parte 
importante e precoce do processo de linfomagénese, contribuindo para a progressão da doença.  
Objectivo: Avaliação da expressão das modificações epigenéticas pós-traducionais das 
histonas H3K4me3 (trimetilação da lisina 4 da histona H3) e H3K27me3 (trimetilação da lisina 
27 da histona H3) e correlação com os parâmetros clínicos e patológicos com o objectivo de 
determinar o seu possível papel como biomarcador de prognóstico em linfoma folicular.  
Material e Métodos: Foi realizado um estudo transversal retrospetivo com base em material 
biológico de arquivo para avaliação da imunoexpressão da marca epigenética H3K4me3 e 
H3K27me3 (utilizando o Hscore), de 48 doentes do Instituto Português de Oncologia do Porto 
diagnosticados entre 2007 e 2012. Foi utilizada a base de dados do Serviço de Oncohematologia 
para obtenção dos dados clínicos e patológicos relevantes. 
Resultados: Com base na análise da sobrevivência, o FLIPI (p<0.001) e a idade foram 
confirmados (p=0.019) como fatores de prognóstico. Na avaliação das marcas epigenéticas 
H3K4me3 e H3K27me3, não se observou associação com a sobrevida global. 
Conclusões: Nesta série, as marcas epigenéticas H3K4me3 e H3K27me3 não revelaram valor 
prognóstico em linfoma folicular. Para um melhor estudo será necessário um alargamento do 
estudo, com um maior número de casos. 
Palavras-Chave: Linfoma não Hodgkin, Linfoma folicular, epigenética, biomarcadores 
moleculares, imunohistoquímica, H3K4me3, H3K27me3, prognóstico  
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Abstract  
 
Background: Follicular lymphoma is the second most common subtype of non-Hodgkin 
lymphoma, accounting for approximately 20% of all newly diagnosed cases, and it is the most 
common indolent non-Hodgkin lymphoma. It is characterized by significant heterogeneity. The 
follicular lymphoma international prognostic index is used to predict outcome, but gives only 
a rough estimate. Additional prognostic markers are under investigation. Epigenetic changes 
are now recognized as playing an important and early role in the lymphomagenesis process, 
contributing to the disease progression. 
Objective: Quantitative evaluation of the expression of the post-translational epigenetic 
modification of H3K4me3 (trimethylation of lysine 4 on histone H3) and H3K27me3 
(trimethylation of lysine 27 of histone 3) in a series of follicular lymphomas through 
immunoexpression and correlation with clinicopathological parameters, to determine its 
relevance as prognostic biomarker. 
Material and Methods: A retrospective transversal study was completed using archival 
biological material from 48 patients with follicular lymphoma, diagnosed between 2007 and 
2012 at the Portuguese Oncology Institute Porto. The H3K4me3 and H3K27me3 marks were 
assessed by immunohistochemistry, using the Hscore. Relevant clinical and pathological data 
was extracted from the database of the Department of Oncohematology.  
Results: In this series, only the FLIPI score (p<0.001) and age at the time of diagnosis (p=0.019) 
were confirmed as a prognostic factor. When evaluating the epigenetic marks H3K4me3 e 
H3K27me3 no significant association with clinical outcome was found. 
Conclusions: In this study, the immunoexpression H3K4me3 and H3K27me3 didn’t show 
prognostic value. A larger study is needed in order to fully determine the relation between 
H3K4me3, H3K27me3 and prognosis. 
Keywords: Non-Hodgkin lymphoma, follicular lymphoma, epigenetics, molecular biomarkers, 
immunohistochemistry, H3K4me3, H3K27me3, prognosis  
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Non-Hodgkin lymphomas (NHL) are a diversified and heterogeneous group of disorders 
derived from the clonal expansion of B-cells, T-cells, or NK cells. 
Among NHL, follicular lymphoma (FL), a low-grade B-cell neoplasm, is the second most 
common histological subtype and the most frequent indolent NHL [1], accounting for 
approximately 20% of all NHL cases. It is characterized by significant heterogeneity [2] with 
regards to clinical presentation, morphological spectrum and overall survival.  
FL usually arises in the lymph nodes, it is most often clinically indolent and grows more slowly 
compared with some other forms of NHL. Although most FLs are at an advanced stage at the 
time of diagnosis, about 50% of the patients survive at least 8 to 10 years after diagnosis, and 
many may not require treatment for a long time. There is no known curative therapy, and 
treatment largely depends on the stage of the disease and, thus, initial staging is paramount [3]. 
FL patients may be treated with a combination of chemotherapy, monoclonal antibodies and/or 
radiation therapy, or they may be followed closely with watchful waiting [3]. Treatment of FL 
is challenging because of frequent recurrence [1]. 
FL occurs in all races and at all geographic locations, but the exact worldwide incidence is not 
known. In Europe, the incidence of FL is approximately 2.18 cases per 100.000 people per year 
[4], whereas in the United States the annual incidence has been estimated as 3.18 per 100.000 
people. There is no difference in incidence between sex. The incidence increases with age, it is 
higher in Caucasians comparing with Africans and Asians [5,6], and it has a peak incidence in 
the fifth and sixth decades of life and it is rare before 20 years of age [7]. Incidence worldwide 
is increasing [1].  
Many risk factors have been suggested. However, many of them have not been sufficiently 
investigated and there are contradictory findings. Immunosuppressant drugs, familial history 
[8], viruses (EBV, HTLV and the herpesvirus associated with Kaposi sarcoma), congenital 
immunodeficiencies [1], hair dyes [9], benzene, toluene and xylene [10] were found to increase 
the risk of NHL. Tobacco use [11,12] and no alcohol consumption [13] were also shown to 
increase the risk of FL, nonetheless these findings remain controversial [14]. 
The natural history of the disease is associated with histologic progression in both pattern and 
cell type. A heterogeneous cytological composition is one of the hallmarks of FL. Usually, all 
follicle centre cell types are represented although in varying proportions. It should be stressed 
that the variation in cytological grade is a continuum, and therefore precise morphologic criteria 
for subclassification are difficult to establish [7].  
According to the WHO criteria [15],  FL are graded into 3 categories, according to the number 
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of centroblasts. All low-grade FLs are combined into a single category, grade 1 to 2, containing 
a predominance of centrocytes with less than 15 centroblasts per high-power field. Grade 3 was 
further subdivided into 3A (centrocytes still present) and 3B (absence of centrocytes). The 
proportion of centroblasts predicts clinical outcome, with a more aggressive course in cases 
with increased number of centroblasts. But an association between grade and clinical outcome 
is controversial. 
Grades 1 and 2, are now, combined into one category (FL1-2 of 3) and the distinction between 
FL3A and FL3B is mandatory. Most patients have stage 3 or 4 disease at diagnosis, with 
generalized lymphadenopathy [7] with only 26% to 33% of patients presenting with stage I to 
II disease [16,17]. Over time, a significant fraction (10-60%) of FL evolves into an aggressive 
lymphoma with a diffuse large cell histology [18,19], at a rate of about 3% each year [19]. 
Histologic transformation is associated with very limited survival [17]. On the other hand, about 
20% of cases are reported to show temporary, spontaneous regression without treatment [20]. 
The staging of FL is made according with the Ann Arbor Classification [3]. 
As previously stated the course of FL is quite variable. The two best measures of outcome at 
the time of diagnosis are the follicular lymphoma international prognostic index (FLIPI) and 
tumour grade. FLIPI includes 5 prognostic factors: age, Ann Arbor stage, haemoglobin level, 
extranodal involvement, and serum LDH level [21].  
FLIPI (follicular lymphoma international prognostic index) has become a clinically useful 
prognostic tool, but gives only a rough estimate of expected outcome, as within each risk group 
there are marked variations in outcome. FLIPI has been devised before the era of anti CD20 
monoclonal antibodies. A revised FLIPI 2 (incorporating β2 microglobulin, diameter of largest 
lymph node, bone marrow involvement and haemoglobin level) has been proposed [22], and, 
more recently, based on the mutational status of seven genes, another prognostic tool, m7- 
FLIPI was developed [23].  
The tumour microenvironment, specifically the immunologic microenvironment comprised of 
T cells and dendritic cells, may influence the development and progression of FL [24]. It has 
been suggested that FL is an immunologically functional disease in which an interaction 
between the tumour cells and the microenvironment determines overall clinical behaviour [24]. 
Thus, there is a need for useful biomarkers for prediction of the disease course [16].  
As FL is defined as a lymphoma of follicle centre B cells, it virtually always demonstrates a 
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growth pattern that is partially follicular [1]. Most (85%) FL [7] are associated with a t(14;18) 
(q32;q21) involving rearrangement of the BCL2 gene and the heavy chain of immunoglobulin 
gene [25]. The translocation occurs after a double-strand break at the IGH locus on chromosome 
14 caused by a defective RAG-mediated VDJ recombination and a break at the BCL2 locus on 
chromosome 18 thought to be linked to an inherent fragility at CpG sites [26]. This translocation 
results in constitutive expression of Bcl-2 protein and thus the inhibition of apoptosis [7]. 
Consequently, the cells of FL accumulate and are at risk to acquire secondary mutations, which 
may be associated with histologic progression. BCL-2 overexpression is virtually always the 
result of this translocation. Less than 10 percent of FL tumours do not harbour BCL-2 
translocations and do not express BCL-2 protein. BCL-2 negativity is most commonly seen in 
grade 3B FL [27].  
As this translocation can be detected in healthy individuals [28], this suggests that it is necessary 
but not sufficient for the development of FL [29] and other genetic and epigenetic lesions as 
well as host factors are required. The early FL progenitors then acquire secondary genetic 
alterations under the influence of activation-induced cytidine deaminase [30]. It is now 
recognized that various genetic abnormalities participate in the generation of FL, and this is 
assumed to constitute a major reason for the clinical heterogeneity of the disease [26].  
Approximately 90 % of FL will demonstrate genetic alterations in addition to the t(14;18) [15]. 
Apart from the t(14;18), the most common chromosomal aberrations include non-random losses 
of 1p36 and 6q as well as gains of 7, 18, and X. It is also important to recognize that epigenomic 
alterations occur in almost every type of cancer. Recent studies have established that activation 
of various oncogenes and silencing of tumour suppressor genes are required for FL 
development and progression [31] highlighting their emerging role as a hallmark of cancer. 
[32]. However, FL appears to be a rather unique malignancy with epigenetic mutations 
occurring in nearly every patient and therefore may represent a valuable model to examine how 
epigenetic perturbations drive cancer in general. Mutations that modify histones are the most 
frequent [31]. 
KMT2D/MLL2 (90%) and EZH2 (25%), both histone methyltransferases, are those which are 
predominantly targeted by mutations, as well as the histone acetyltransferases CREBBP (30–
60%), EP300 (9%), and MEF2B (15%) with almost 80% of cases having co-occurring 
mutations [26,33]. These somatic mutations are predominantly inactivating except those 
affecting EZH2 [33]. The way the EZH2 mutation promotes lymphomagenesis is the best 
characterized [31].  
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Histone methyltransferases are essential in regulating gene expression by modifying two key 
lysine residues: the histone 3 lysine position 4 (H3K4, KMT2D) and histone 3 lysine position 
27 (H3K27, EZH2, CREBBP and EP300) marks. Promoters of actively transcribed genes are 
marked by the presence of a trimethyl mark on histone 3 lysine 4 (H3K4me3). By contrast, 
inactive genes display methylation at lysine 27 (H3K27me3) [34].  
In FL it is thought that the prevailing consequence of the mutations in the histone-modifying 
enzymes is a shift towards aberrant repression of gene transcription by loss of active marks of 
transcription, catalysed by KMT2D and CREBBP/EP300, and increase in the repressive mark 
H3K27me3 through mutations in EZH2 [31]. 
The incorporation of epigenetic mutations has led to improved prognostic tools m7-FLIPI 
combining clinical factors with mutations in seven genes including CREBBP, ARID1A, EP300 
and EZH2.  EZH2 mutations were associated with good risk disease in patients with high-risk 
FLIPI [23], in contrast to what was found in several other tumour models where the increased 
expression of EZH2 is related to worse prognosis and to an increase of the capacities of invasion 
and tumour progression [35,36]. 
An epigenetic alteration that has received considerable interest is the trimethylation of H3K27, 
a gene silencing mark residue [37,38], catalysed by the EZH2, subunit of the Polycomb2 
complex (PRC2) [39].  
EZH2 mediates repression of gene transcription. It was found that EZH2 mutations in 
lymphoma were heterozygous, suggesting that such cancer cells were haploinsufficent for the 
enzymatic activity. The results could be a global deficit of H3K27 methylation and widespread 
derepression of gene expression [34,40].  
There are conflicting findings regarding the association between EZH2 mutation and overall 
survival or time to transformation. While Pastore et al. [23] found that the presence of EZH2 
mutations was associated with improvement in both failure-free survival and overall survival, 
in a different study [41] no association between EZH2 mutation and these variables was found.  
Immunohistochemical staining performed on previously constructed tissue microarrays 
demonstrated variable expression of EZH2 and H3K27me3 in FL independent of EZH2 
mutation status which supports that mechanisms other than gene mutation are affecting EZH2–
H3K27me3 levels [41].  
There are many opportunities to explore the mutations affecting epigenetic factors from a 
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therapeutic perspective. Although epigenetic therapies such as histone deacetylase inhibitors 
have previously been evaluated in FL, results were largely disappointing [42,43]. In parallel 
with these genetic discoveries, there has been a rapid development of inhibitors targeting EZH2 
histone methyltransferase activity, which are demonstrating promising results in both in vitro 
and in vivo models. At present, three compounds have proceeded to early phase clinical trials 
in patients, emerging Phase I data suggest a potential role in EZH2 wild-type tumours [31].  
KMT2D, also known as MLL2, codes a histone methyltransferase responsible for histone H3 
lysine 4 (H3K4) trimethylation and belongs to the KMT2 family. This family of histone 
methyltransferases has been implicated in an extensive range of malignancies and is among the 
most frequent alterations in human cancer [44], its mutation represents an early event [45]. The 
majority of genetic alterations in this enzyme lead to truncated proteins, through decreased 
methylation of H3K4, resulting in the repression of gene expression [31]. 
 Objective 
The main goal of this project was to quantitatively evaluate the expression of the post-
translational histone modifications H3K4me3 and H3K27me3 in a series of follicular 
lymphomas diagnosed and treated at Portuguese Oncology Institute of Porto, between 2007 and 
2012, to determine its value as a prognostic and, possibly, predictive biomarker of therapeutic 
response.  
 
Materials and Methods 
This study is integrated within the scope of the PhD project of Dr. Margarida Dantas de Brito 
Rodrigues, entitled “Epigenética e linfomagénese – O papel das enzimas modificadoras de 
histonas no linfoma difuso de grandes células B e no linfoma follicular”, which was approved 
by ethics committee (Comissão de Ética para a Saúde) of IPO Porto (CES 216/2012). 
 
Patients and samples 
Tissue biopsies from patients consecutively diagnosed with follicular lymphoma at Portuguese 
Oncology Institute of Porto (IPO Porto, a tertiary healthcare institution) from 2007 to 2012 
were enrolled. All slides were reviewed and a representative block was selected for 
immunohistochemistry. 
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Clinical data was retrieved from patients’ charts (dates of birth, diagnosis, treatment start, death; 
clinical stage (CS); FLIPI; treatments performed; evidence of clinical recurrence/progression; 
last follow-up date and vital status). Follow-up was updated as of 30th April, 2017. Patient death 
was rendered as FL-related (death from disease – DFD) when patients died due to disease 
progression or in the sequence of treatments performed, or as FL-unrelated (including either 
death with disease – DWD – or death with no evidence of disease – D-NED). 
 
Immunohistochemistry and image analysis 
Immunohistochemistry was performed using Novolink™ Max Polymer Detection System 
(Leica Biosystems, Germany). Sections (3µm-thick) were cut and microwaved for 20mins in 
citrate buffer at 800W for antigen retrieval. Endogenous peroxidase was blocked through 
incubation in hydrogen peroxide in 3% methanol for 30mins. Primary antibodies for H3K4me3 
(polyclonal, clone ab8580, Abcam, Cambridge, United Kingdom) and H3K27me3 (monoclonal, 
clone C36B11, Cell Signaling Technology, Danvers, MA, USA) were used at 1:1000 and 1:500 
dilution in 1% PBS-BSA, respectively, and incubated for 1hr and overnight at 4ºC, respectively. 
3,3'-diaminobenzidine (Sigma-Aldrich™, Germany) was used for visualization and 
hematoxilin for nuclear counterstaining. Appropriate positive controls were used for each 
antibody and negative control consisted on omission of primary antibodies.  
A digital image analysis system (GenASIs™, Israel) was used for H3K4me3 and H3K27me3 
nuclear immunostaining quantification. Nuclei were considered positive if any staining was 
present, independently of intensity. Multiple fields of view were selected per slide, in order to 
analyse at least 5 different fields or 5000 cells. This analysis allowed the quantification of the 
proportion of immunostained cells, its intensity, and the Hscore (weighting between the 
percentage of marked cells and the intensity of the staining). 
 
Statistical analysis 
For analysis purposes, patients were divided into two Clinical Stage (CS) groups (stage I/II, 
stage III/IV). Cutoffs for H3K4me3 and H3K27me3 nuclear immunostaining (high vs. low) 
were set at 25th and 50th percentile (P25 and P50). Association between biomarkers’ distribution 
and CS was evaluated using Chi-square test. Distribution of continuous variables between 
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groups was compared using non-parametric tests (Mann-Whitney or Kruskall-Wallis, as 
appropriate). Survival curves were constructed using Kaplan-Meier non-parametric estimator. 
Survival between groups was compared using Log-rank test. Statistical significance was set at 
p<0.05. Statistical analysis was performed using SPSS® Statistics for Windows, version 24.0 
(SPSS, Chicago, IL, USA). 
Results 
Clinical and pathological characterization of the patients 
Forty-eight patients with FL were included in this study. The clinical and pathological 
characteristics are shown in Table 1. In this sample, 27 % of patients were male, and the median 
age at diagnosis was 60 years. Recurrent/transformed disease was experienced by 34% of the 
patients. 
Table	1	Clinical	and	pathological	characteristics	of	the	patients	
	 	 N	 %	
Gender	 Female	 35	 72.9	
Male	 13	 27.1	
Age	at	Diagnosis	 ≤60	years	 26	 54.2	
>60	years	 22	 45.8	
Ann	Arbor	Stage	 I/II	 5	 11.4	
III/IV	 40	 88.6	
FLIPI	
Low	risk	(0,1)	 5	 12.2	
Intermediate	risk	(2,3)	 25	 61.0	
High	risk	(4,5)	 11	 26.8	
 
 
Overall survival 
At the end of the study and using the date of the last consultation, the follow-up time was 
determined and the median was 71.5 months (range: 52.6 – 113.2 months). The overall survival 
was estimated as 91.3% at 2 years and 74.7% at 5 years. The disease-specific survival was 
estimated as 91.3% at 2 years and 77.3% at 5 years. 
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Factors that impacted on disease-specific survival 
In the survival analysis, we considered the association between the disease-specific survival 
and the FLIPI score, Ann Arbor stage and age at the time of diagnosis. In our sample, the Ann 
Arbor stage was not associated with prognosis (p=0.609), whereas FLIPI score and age at the 
time of diagnosis were (p<0.001 and p=0.019, respectively). A lower FLIPI score and a lower 
age at diagnosis were associated with a better outcome. No difference in prognosis was 
observed concerning gender (p=0.755).  
	Fig.	1	Overall	survival	of	patients	with	FL.	
Fig.	2,	3	Analysis	of	disease-specific	survival	according	to	Ann	Arbor	stage	and	gender.	
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Immunohistochemistry profile:  
The immunoexpression of the epigenetic markers was studied in the cells’ nuclei. To evaluate 
the immunoexpression, the Hscore was used. 
 
H3K4me3 
In this epigenetic mark, Hscore varied between 89.20 and 300, with a median of 292.60. 
In the statistical analysis of the distribution of Hscore of H3K4me3 according to gender, age, 
Fig.	4	Analysis	of	disease-specific	survival	according	to	grouped	FLIPI	score.	
Fig.	5	Analysis	of	disease-specific	survival	according	to	age	(>60	years,	£60	years).	
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Ann Arbor stage, transformation and FLIPI there were no statistically significant associations. 
We used Mann Whitney’s test for all the variables except for FLIPI score, in which Kruskal 
Wallis’ test was used. (Table 2). 
Table	2	Comparison	between	Hscore	and	clinical	and	pathological	parameters	
	 p	
Gender	 0.609	
Age	(≤60/>60	years)	 0.543	
Ann	Arbor	Stage	 0.355	
Transformation	 0.762	
FLIPI	 0.292	
 
The immunoexpression of H3K4me3 was not associated with the disease-specific survival 
using either the median (p=0.105) or the 25th percentile (p=0.179) as cutoff values.  
 
 
 
Fig.	6,7	Analysis	of	disease-specific	survival	by	Hscore:	in	the	left	panel,	the	comparison	is	
made	using	the	median	(292.60)	and	in	the	right	panel	the	25th	percentile	(204.60).	
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H3K27me3 
The Hscore varied between 52.2 and 299.9, with a median of 287.65. 
In the statistical analysis of the distribution of Hscore of H3K27me3 according to gender, age, 
Ann Arbor stage and transformation there were no statistically significant results except for 
FLIPI score (p = 0.038). We used Mann Whitney’s test for all the variables except for FLIPI 
scale, in which the Kruskal Wallis’ test was used. (Table 3). 
Table	3	Comparison	between	Hscore	and	clinical	and	pathological	characteristics	
	 p	
Gender	 0.862	
Age	(≤60/>60	years)	 0.444	
Ann	Arbor	Stage	 0.644	
Transformation	 0.931	
FLIPI	 0.038	
 
The immunoexpression of H3K27me3 was not associated with disease-specific survival using 
either the median (p=0.894) or the 25th percentile (p=0.207).  
 
Fig.	8,9	Analysis	of	disease-specific	survival	by	Hscore:	in	the	left	panel,	the	comparison	is	
made	using	the	median	(287.65),	and	in	the	right	panel	using	the	25th	percentile	(183.05).	
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Discussion 
Follicular lymphoma is a clinically heterogeneous disease [16]. Although FL is most often 
clinically indolent, most FLs are at an advanced stage at the time of diagnosis [46]. More 
importantly, over time, a significant fraction evolves into an aggressive lymphoma [18,19]. 
Different tools have been devised to predict the prognosis of FL [21-23] and albeit these are 
clinically useful prognostic tool they only provide a rough estimate of the expected outcome 
[16]. Therefore, there is a need for useful biomarkers that more accurately predict disease course, 
therapy response and identifying the subset of patients at higher risk of early treatment failure 
and transformation [2,23]. 
This study was based in a series of patients diagnosed with FL and treated at IPO-Porto between 
2007 and 2012. The median age (60 years) at the diagnosis is in accordance with the literature 
[1]. In comparison with published data [4], this series had an over-representation of women 
(2.70:1), also the number of patients with a clinical stage I/II was only 11% in comparison to 
the 26-33% usually found [16]. The proportion of patients with transformation/recurrence was 
34%, well within the 10-60% previously reported [18]. In our sample, contrary to what was 
expected, the Ann Arbor stage was not associated with prognosis but the FLIPI score and age 
at the time of diagnosis were. This may mean that this series was not representative of the 
population diagnosed with FL. 
As discussed in the previous section, two epigenetic marks were analysed: H3K4me3 and 
H3K27me3. In FL, it is thought that the prevailing consequence of the mutations in the histone-
modifying enzymes is a shift towards aberrant repression of gene transcription. When 
evaluating the expression H3K4me3, it was observed that this mark was found to be expressed 
in variable levels but no significant association between this epigenetic mark and survival was 
found. Di- and trimethylation of H3K4 is linked to transcriptional activation and high levels of 
H3K4me3 trimethylation are associated with the promoters of actively transcribed genes [47]. 
A decrease of H3K4me2/me3 is observed in a range of neoplastic tissues (i.e. prostate, lung, 
breast and pancreatic cancer) [48,49]. In this series of FL patients we were expecting that a 
decrease of this marker might correlate with a worse prognosis. There are several enzymes that 
affect H3K4: MLL family of histone methyltransferases and LSD1 and JARID1 family of 
histone demethylases [47]. These enzymes have been shown to have altered activity in cancer 
[49]. Almost 90% of patients with FL have mutations on KMT2D [33], these mutations point 
to its loss of function leading to decreased methylation of H3K4, resulting in the repression of 
gene expression [31] and this suggests its role as a tumour suppressor gene [50,51].  
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LSD1 histone demethylase is responsible for the demethylation of H3K4 and H3K9, decreasing 
the methylation and promoting gene silencing [52]. LSD1 expression correlates with adverse 
outcome [49]. The levels of LSD1 are significantly increased in bladder, acute myeloid 
leukaemia, prostate and colorectal neoplasms [53], but no published data is available 
concerning altered LSD1 expression in FL. The decrease of the KMT2D activity with an 
increase in the activity of LSD1 could be an explanation for the decrease in methylation in this 
series. 
When evaluating H3K27me3, which is a mark that acts as a repressor, we were expecting its 
increase to be correlated with a worse prognosis. However, no significant association between 
this epigenetic mark and survival was found. The trimethylation of lysine 27 on histone H3 
(H3K27me3) is an epigenetic mark associated with transcriptional silencing by promoting a 
compact chromatin structure [49] and it is catalysed by EZH2 [41]. This enzyme is expressed 
in developing B-cells in a stage-dependent manner [34]: during early B-cell development EZH2 
is required for VDJ recombination and it is subsequently downregulated in mature B-cells, but 
it is highly expressed again after T-cell dependent activation in germinal centre B-cells [54]. 
Interestingly, 25% of patients with FL were found to have an EZH2 mutation. These mutations 
result in a gain of function [31]. In several other tumour models the increased expression of 
EZH2 is related to worse prognosis and to an increase of invasion and tumour progression 
capacity [35,36]. Overexpression of EZH2 has been demonstrated to occur in diverse cancers, 
including those of the prostate, breast, kidney and ovary and may cause silencing of growth 
suppressive genes [35,55,49]. There are conflicting findings regarding the association between 
EZH2 mutation and overall survival or time to transformation. It was found that the presence 
of EZH2 mutations was associated with improvement in both failure-free survival and overall 
survival [23], in a different study [41] it did not appear to affect clinical outcome. In general, 
EZH2 overexpression in cancer cells seems to result in an EZH2-dependent increase in 
H3K27me3. However, no association was found between EZH2 and H3K27me3 expression in 
breast, ovarian and pancreatic cancers [56]. H3K27me3 in FL seems to be independent of EZH2 
mutation status which supports that mechanisms other than gene mutation are affecting EZH2–
H3K27me3 levels [41]. 
One explanation for the absence of significant association between EZH2 and H3K27me3 
might lie in the H3K27me3 demethylases. H3K27me3 marks are removed by the JMJD3 and 
UTX [57]. Inactivating alterations of UTX were recently reported in a variety of tumours, 
particularly in multiple myeloma [58]. JMJD3 has also been linked to tumour development and 
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it is induced by Epstein–Barr virus and overexpressed in Hodgkin’s lymphoma [59]. This 
suggests that both an increase or a decrease of H3K27 methylation activity may lead to 
malignancy, so a precise balance of this methylation is critical for normal cell growth [34]. 
Another group of enzymes that affects H3K27 are the histone acetyltransferases CREBBP and 
EP300. In FL, there is a loss of function of these enzymes resulting in inactivating genetic 
alterations that contribute to a repressed gene expression state through decreased acetylation of 
H3K27 (H3K27ac) and other target proteins [31,54]. 
Although some reports suggested that there was conservation of methylation profiles between 
pre- and post-transformation FL samples [60], which could mean that epigenetic biomarker 
may not be useful in predicting prognosis, with the introduction of higher resolution measurable 
differences in relapsed and more aggressive tumours were found [31].  
There are some limitations that can be pointed out in this study. First, the size of the sample 
might be too small to ascertain any significant association between epigenetic marks and 
prognosis. Second, some characteristics of the series were not according to what would be 
expected, most notably the fact that there was no association between the Ann Arbor stage and 
prognosis and also an unbalanced number of patients with an Ann Arbor stage III/IV. Also, the 
evaluation of the Hscore is subject to intra- and inter observer variability, even though it was 
performed using GenASIs™ Software which helps reducing the variability. 
In conclusion, a better understanding of the mechanism leading to B-cell lymphomas was 
brought by recently discovered epigenetic lesions, but more studies are needed to better clarify 
their role and clinical relevance. Epigenetic lesions are an opportunity for the development of 
improved biomarkers as well as cancer therapies.  
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Annex	I:	Imunoexpression	of	H3K27me3,	with	respective	Hscore,	number	of	analysed	
cells	and	percentage	of	positive	cells.		
Case	number	 Hscore	 Number	of	analysed	cells	 Percentage	of	positive	cells	
1	 299.5	 9311	 99.8	
2	 297.1	 6493	 99.0	
3	 299.3	 8258	 99.8	
4	 298.6	 6828	 99.5	
5	 299.1	 7708	 99.7	
6	 296.2	 8889	 98.7	
7	 298.1	 6946	 99.4	
8	 298.1	 7079	 99.4	
9	 298.9	 7294	 99.6	
10	 153.2	 4854	 51.1	
11	 145.0	 6737	 48.3	
12	 293.2	 10879	 97.7	
13	 292.1	 9017	 97.4	
14	 298.6	 7507	 99.5	
15	 288.8	 5741	 96.3	
16	 52.2	 4383	 17.4	
17	 207.7	 11475	 69.2	
18	 293.4	 9916	 97.8	
19	 294.7	 6443	 98.2	
20	 286.5	 8137	 95.5	
21	 297.0	 12897	 99.0	
22	 299.2	 7831	 99.7	
23	 223.0	 7216	 74.3	
24	 240.4	 4371	 80.1	
25	 286.8	 7491	 95.6	
26	 266.6	 5821	 88.9	
27	 294.6	 8714	 98.2	
28	 205.0	 3395	 68.3	
29	 299.9	 7687	 100	
30	 276.0	 4897	 92.0	
31	 299.9	 8365	 100	
32	 60.9	 4831	 20.3	
33	 198.5	 6695	 66.2	
34	 33.6	 5775	 11.2	
35	 177.9	 5477	 59.3	
36	 212.3	 11203	 70.8	
37	 299.6	 6178	 99.9	
38	 255.0	 5338	 85.0	
39	 288.5	 8087	 96.2	
40	 299.9	 6692	 100	
41	 124.0	 3917	 41.3	
	 24	
42	 113.8	 5119	 37.9	
43	 78.9	 5197	 26.3	
44	 152.0	 5995	 50.7	
45	 74.4	 3011	 24.8	
46	 298.6	 6725	 99.5	
47	 61.5	 4811	 20.5	
48	 265.9	 5615	 88.6	
49	 151.6	 5507	 50.5	
50	 79.0	 3698	 26.3	
51	 285.0	 6656	 95.0	
52	 251.1	 4364	 83.7	
Control	(Liver)	 222.7	 10465	 74.2	
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Annex	II:	Imunoexpression	of	H3K4me3,	with	respective	Hscore,	number	of	analysed	
cells	and	percentage	of	positive	cells.		
 
Case	number	 Hscore	 Number	of	analysed	cells	 Percentage	of	positive	cells	
1	 298.4	 7935	 99.5	
2	 299.8	 7467	 99.9	
3	 299.2	 9098	 99.7	
4	 299.5	 7122	 99.8	
5	 299.3	 9205	 99.8	
6	 299.3	 8757	 99.8	
7	 299.8	 10646	 99.9	
8	 299.6	 7630	 99.9	
9	 296.0	 7955	 98.7	
10	 168.1	 5625	 56.0	
11	 233.4	 5902	 77.8	
12	 287.3	 5972	 95.8	
13	 268.8	 7073	 89.6	
14	 299.3	 8837	 99.8	
15	 291.5	 10905	 97.2	
16	 89.2	 6233	 29.7	
17	 193.5	 7847	 64.5	
18	 299.5	 9103	 99.8	
19	 299.8	 8633	 99.9	
20	 299.2	 9214	 99.7	
21	 299.3	 9226	 99.8	
22	 299.9	 9311	 100	
23	 292.5	 7236	 97.5	
24	 292.6	 5615	 97.6	
25	 299.7	 8334	 99.9	
26	 265.6	 3178	 88.5	
27	 247.1	 11357	 82.4	
28	 206.5	 7202	 68.8	
29	 298.3	 7750	 99.4	
30	 171.1	 6670	 57.0	
31	 300.0	 8932	 100	
32	 102.3	 5843	 34.1	
33	 299.2	 9311	 99.7	
34	 216.5	 5800	 72.2	
35	 155.9	 5138	 52.0	
36	 265.0	 9634	 88.3	
37	 299.7	 7949	 99.9	
38	 167.0	 5874	 55.7	
39	 255.1	 6135	 85.0	
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40	 299.3	 7879	 99.8	
41	 206.5	 2797	 68.8	
42	 204.6	 5911	 68.2	
43	 192.4	 7520	 64.1	
44	 187.5	 4799	 62.5	
45	 190.2	 3516	 63.4	
46	 299.9	 7993	 100	
47	 140.9	 4625	 47.0	
48	 198.8	 6410	 66.3	
49	 189.3	 6133	 63.1	
50	 228.2	 3547	 76.1	
51	 298.5	 9704	 99.5	
52	 183.8	 5476	 61.3	
Control	(Liver)	 204.4	 6035	 68.1	
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Annex	III:	GenASIs™	Software	
 
 
 
 
 
